Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5201435
Max Phase: Preclinical
Molecular Formula: C56H96N22O10
Molecular Weight: 1237.53
Associated Items:
ID: ALA5201435
Max Phase: Preclinical
Molecular Formula: C56H96N22O10
Molecular Weight: 1237.53
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)CCC(=O)N[C@@H](CCCCNC(=O)[C@@H](CCCNC(=N)N)NC(=O)CCCCCCCC(=O)N1CCN(c2ncnc3[nH]ccc23)CC1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O)C(=O)NCC(C)=O
Standard InChI: InChI=1S/C56H96N22O10/c1-4-35(2)46(53(88)69-33-36(3)79)76-44(82)22-21-43(81)73-40(51(86)75-41(18-14-27-68-56(62)63)52(87)74-38(47(57)84)16-12-25-66-54(58)59)15-10-11-24-65-50(85)39(17-13-26-67-55(60)61)72-42(80)19-8-6-5-7-9-20-45(83)77-29-31-78(32-30-77)49-37-23-28-64-48(37)70-34-71-49/h23,28,34-35,38-41,46H,4-22,24-27,29-33H2,1-3H3,(H2,57,84)(H,65,85)(H,69,88)(H,72,80)(H,73,81)(H,74,87)(H,75,86)(H,76,82)(H4,58,59,66)(H4,60,61,67)(H4,62,63,68)(H,64,70,71)/t35-,38+,39+,40-,41+,46-/m0/s1
Standard InChI Key: TURTYWRBJHWUDZ-WDMGAOPMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1237.53 | Molecular Weight (Monoisotopic): 1236.7680 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Sõrmus T, Lavogina D, Teearu A, Enkvist E, Uri A, Viht K.. (2022) Construction of Covalent Bisubstrate Inhibitor of Protein Kinase Reacting with Cysteine Residue at Substrate-Binding Site., 65 (16.0): [PMID:35960538] [10.1021/acs.jmedchem.2c00067] |
Source(1):